Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function

Journal of Hypertension

Volumn 20, Issue 1, 2002, Pages 71-78

  Schiffrin, Ernesto L ^a   Park, Jeong Bae ^a   Pu, Qian ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Antihypertensive therapy; AT1 receptor; Blood pressure; Endothelium; Hypertrophy; Remodeling

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROCHLOROTHIAZIDE; IRBESARTAN;

ADULT; ARTERY DIAMETER; ARTERY MEDIA; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANCE BLOOD VESSEL; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

EID: 0036060584     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200201000-00011     Document Type: Article

References (51)

1. Effects of a β-blocker or a converting enzyme inhibitor on small arteries in essential hypertension
2. Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a beta-blocker
3. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension
4. Comparison of effects of angiotensin I-converting enzyme inhibition and β-blockade for 2 years on function of small arteries from hypertensive patients
5. Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy
6. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan
7. Blockade of angiotensin II type 1 receptors: Effect on carotid and radial artery structure and function in hypertensive humans
8. Structure and function of resistance arteries of hypertensive patients treated with a β-blocker or a calcium channel antagonist
9. Effect of treatment on morbidity in hypertension, II: Results in patients with diastolic blood pressure averaging 90 through 114 mmHg
10. MRC trial of treatment of mild hypertension: Principal results
11. Australian Therapeutic Trial in mild hypertension
12. MRC trial of treatment of hypertension in older adults: Principal results
13. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP)
14. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
15. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
16. Hypertension STOP. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study
17. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
18. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
19. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: Overview of randomized drug trials in their epidemiological context
20. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction
21. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
22. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells
23. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-β1 expression determines growth response to angiotensin II
24. Role of extracellular signal-regulated kinases in angiotensin II-stimulated contraction of smooth muscle cells from human resistance arteries
25. Role of angiotensin II and bradykinin on aortic collagen following converting enzyme inhibition in spontaneously hypertensive rats
26. Evidence for increased media thickness, increased neuronal amine uptake, and depressed excitation-contraction coupling in isolated resistance vessels from essential hypertensives
27. Mechanics and composition of human subcutaneous resistance arteries in essential hypertension
28. Angiotensin II type 2 receptor mediates programmed cell death
29. 1 receptor-mediated prostaglandin E2 production in conscious rats
30. 2 angiotensin receptors in apoptosis in rat blood vessels
31. Vascular remodeling
32. Histology of subcutaneous small arteries from patients with essential hypertension
33. Morphology of small arteries and comparison of effects of vasoconstrictors in mild essential hypertensive patients
34. Vascular remodeling in hypertension: Roles of apoptosis, inflammation and fibrosis
35. Acute and chronic effects of drugs with different actions on adrenergic receptors: A comparison between alpha blockers and different types of beta blockers with and without vasodilating effect
36. G-nitro-L-arginine meethyl ester treatment does not prevent flow-induced remodeling in mesenteric feed arteries and arcading arterioles
37. Disparate effects of carvedilol versus metoprolol treatment of stroke-prone spontaneously hypertensive rats on endothelial function of resistance arteries
38. The relation between peripheral vascular structure, left ventricular hypertrophy, and ambulatory blood pressure in essential hypertension
39. Preserved endothelium-dependent vasodilation in patients with essential hypertension
40. Abnormal endothelium dependent vascular relaxation in patients with essential hypertension
41. Indirect evidence for release of endothelium-derived relaxing factor in the human forearm circulation in vivo: Blunted response in essential hypertension
42. Small artery remodeling is the most prevalent (earliest?) manifestation of target organ damage in hypertension
43. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells
44. Superoxide production, risk factors, and endothelium-dependent relaxations in human internal mammary arteries
45. In vitro responses of human peripheral small arteries in hypercholesterolemia and effects of therapy
46. Correlation of endothelial function in large and small arteries in human essential hypertension
47. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease
48. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study
49. Differences between blood-pressure-lowering drugs
50. Blood pressure control and benefits of antihypertensive therapy. Does it make a difference what agents we use?
51. Are β-blockers efficacious as first-line therapy for hypertension in the elderly?